Trials / Terminated
TerminatedNCT00171860
A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of the study are: 1. Evaluation of the safety profile of imatinib mesylate in patients with idiopathic hypereosinophilic syndrome resistant or refractory to, or intolerant of, prednisone, hydroxyurea or interferon-alpha, or untreated patients carrying the Fip1L1-PDGFRA fusion protein. 2. Evaluation of the efficacy of imatinib mesylate in patients with idiopathic hypereosinophilic syndrome 3. Analysis of patient's blood samples for the detection of activated kinases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | imatinib mesylate |
Timeline
- Start date
- 2002-09-01
- Primary completion
- 2007-07-01
- First posted
- 2005-09-15
- Last updated
- 2012-05-01
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT00171860. Inclusion in this directory is not an endorsement.